0001493152-23-041323.txt : 20231114 0001493152-23-041323.hdr.sgml : 20231114 20231114172246 ACCESSION NUMBER: 0001493152-23-041323 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231114 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELITE PHARMACEUTICALS INC /NV/ CENTRAL INDEX KEY: 0001053369 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223542636 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15697 FILM NUMBER: 231408053 BUSINESS ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 BUSINESS PHONE: 2017502646 MAIL ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 FORMER COMPANY: FORMER CONFORMED NAME: ELITE PHARMACEUTICALS INC /DE/ DATE OF NAME CHANGE: 19980121 8-K 1 form8-k.htm
false 0001053369 0001053369 2023-11-14 2023-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

November 14, 2023

Date of Report (Date of earliest event reported)

 

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-15697   22-3542636
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

 

(201) 750-2646

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ELTP   OTCQB

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 14, 2023, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) filed its quarterly report on Form 10-Q for the quarter ended September 30, 2023, and thereafter, issued a press release announcing its financial results for that quarter. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

As noted in the press release, the Company will host a conference call at 11:30 AM Eastern Standard Time (EST) on Wednesday, November 15, 2023, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.

 

Conference Call Information

 

Date: November 15, 2023
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
Financial questions by 7:00 PM EST on Tuesday, November 14, 2023
Audio Replay: https://elite.irpass.com/events_presentations

 

Item 7.01 Regulation FD Disclosure.

 

The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated November 14, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 14, 2023 ELITE PHARMACEUTICALS, INC.

 

  By: /s/ Nasrat Hakim
    Nasrat Hakim, President and CEO

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023

and Provides Conference Call Information

 

Conference Call Scheduled for Wednesday, November 15 at 11:30 AM EST

 

Northvale, NJ – November 14, 2023: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the second quarter of fiscal year 2024 ended September 30, 2023 (“Second Quarter”).

 

Consolidated revenues for the three-month period ended September 30, 2023, were $14.2 million, an increase of $5.6 million or 64.9% as compared to the comparable period of the prior fiscal year. Operating profits were $1.9 million, an increase of $0.8 million or 78.1% from the comparable period of the prior year. Net income attributable to common shareholders was $14.9 million, an increase of $13.4 million or 886% from the comparable period of the prior year. The increase in operating profits was primarily attributed to increased revenues achieved from the launch of the Elite Laboratories label product line during the quarter ended June 30, 2023.

 

Conference Call Information

 

Elite’s management will host a conference call to discuss the Second Quarter financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.

 

Date: November 15, 2023
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
Financial questions by 7:00 PM EST on Tuesday, November 14, 2023
Audio Replay: https://elite.irpass.com/events_presentations

 

The financial statements can be viewed for Elite’s Second Quarter of Fiscal Year 2024 on Form 10-Q here.

 

About Elite Pharmaceuticals, Inc.

 

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

 

For Elite Pharmaceuticals, Inc.

Dianne Will, Investor Relations, 518-398-6222

Dianne@elitepharma.com

www.elitepharma.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 eltp-20231114.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 eltp-20231114_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 eltp-20231114_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 14, 2023
Entity File Number 001-15697
Entity Registrant Name ELITE PHARMACEUTICALS, INC
Entity Central Index Key 0001053369
Entity Tax Identification Number 22-3542636
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 165 Ludlow Avenue
Entity Address, City or Town Northvale
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07647
City Area Code (201)
Local Phone Number 750-2646
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ELTP
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001053369 2023-11-14 2023-11-14 iso4217:USD shares iso4217:USD shares false 0001053369 8-K 2023-11-14 ELITE PHARMACEUTICALS, INC NV 001-15697 22-3542636 165 Ludlow Avenue Northvale NJ 07647 (201) 750-2646 false false false false false Common Stock, par value $0.001 per share ELTP EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " M 4(0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #6BFY7)!Z;HJT #X M 0 &@ @ &B$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " #6BFY799!YDAD! #/ P $P @ &' L$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #1$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://elitepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports eltp-20231114.xsd eltp-20231114_lab.xml eltp-20231114_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "ELTP", "nsuri": "http://elitepharma.com/20231114", "dts": { "schema": { "local": [ "eltp-20231114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "eltp-20231114_lab.xml" ] }, "presentationLink": { "local": [ "eltp-20231114_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 21 }, "report": { "R1": { "role": "http://elitepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://elitepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-041323-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-041323-xbrl.zip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